Last checked at 
LONDON (Alliance News) - Tissue Regenix Group PLC presented the results of its patient study into the efficacy of its dCELL aortic heart valves at an event in Milan on Monday.
The regenerative medical devices company said its dCELL technology could provide a more effective treatment than cryopreserved aortic valve substitutes.
"We are very happy with the results in this young, high risk patient population, the incidence of reoperation is very low and the results are promising. The evaluation continues and we hope to see on-going progress based on this dCELL regenerative medicine treatment," said Professor Francisco da Costa in a statement, a cardiac surgeon from Pontifical University of Parana in Brazil.
Tissue Regenix shares were trading 2.4% lower Monday mid-morning at 23.66 pence.
By Rowena Harris-Doughty; rowenaharrisdoughty@alliancenews.com; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.e
